The role of non-coding RNAs in the coronary no-reflow phenomenon: a systematic review Authors: Adam Sukiennik, Dominika Tomkiel, Grzegorz Procyk Published: 2026 ABSTRACT AbstractCoronary no-reflow poses a challenge in interventional cardiology. Increasing attention has been directed toward the potential role of non-coding RNAs (ncRNAs) in predicting coronary no-reflow (CNR), with no prior systematic review available to date. We aimed to systematically review the available evidence on the potential clinical utility of ncRNAs in CNR and/or microvascular obstruction (MVO). Embase, MEDLINE Ultimate, PubMed, Scopus, and Web of Science were searched, last on February 9, 2026. Studies enrolling adult patients with CNR and/or MVO that evaluated the expression of ncRNAs or investigated genetic variants within ncRNA-related pathways were included. Risk of bias was not assessed. Upregulation of miR-1, miR-7a/b, miR-98-5p, miR-133a, miR-133b, miR-208a, miR-224-3p, miR-660-5p, long non-coding RNA (lncRNA) TUG1, lncRNA MALAT1, and downregulation of miR-30e, miR-126, miR-155, and miR-542-3p were reported in patients with STEMI with CNR and/or MVO compared with those without CNR/MVO. Almost all ncRNAs were reported by a single study, with the exception of miR-30e, which was consistently reported in three independent studies. Several ncRNAs may demonstrate good performance in identifying patients at risk of CNR and/or MVO occurrence. Nevertheless, the available evidence is scarce and limited by the low robustness of the reported findings. Circulating ncRNAs are promising biomarkers for CNR. Nevertheless, several limitations persist, highlighting the need for further studies with standardized methodology to validate the clinical utility of ncRNAs.Keywords: No-reflow, MicroRNA , Non-coding RNA, PCI Introduction Ischemic heart disease (IHD) remains one of the leading causes of mortality worldwide [1, 2]. Recent years have brought significant advances in percutaneous coronary interventions (PCIs), contributing to improved procedural success and better clinical outcomes in selected patients with IHD [3]. Nevertheless, interventional cardiologists still face important challenges, one of which is the coronary no-reflow (CNR) phenomenon [4]. CNR is defined as inadequate myocardial tissue perfusion despite successful restoration of epicardial coronary artery patency [5, 6]. In clinical practice, CNR is typically assessed using angiographic parameters such as Thrombolysis In Myocardial Infarction (TIMI) flow grade and myocardial blush grade (MBG). Although reduced epicardial flow (TIMI < 3) may suggest CNR, impaired myocardial perfusion can also be present despite TIMI 3 flow [5, 6]. The reported incidence of CNR varies depending on the diagnostic method used and the clinical setting [7]. Regardless of the assessment method, CNR occurs particularly often after primary PCI in patients presenting with ST-segment elevation myocardial infarction (STEMI) [5, 8]. The pathophysiology of CNR is complex and multifactorial, involving distal embolization of atherothrombotic material, ischemic injury to the microcirculation, reperfusion injury, and individual susceptibility of the microvasculature [4, 9]. Together, these factors may result in microvascular obstruction (MVO), which plays a central role in the development of the CNR phenomenon [6, 9]. Clinically, CNR is associated with worse outcomes, including larger infarct size, reduced left ventricular ejection fraction (LVEF), higher rates of arrhythmias and heart failure, as well as increased short- and long-term mortality [10–12]. Therefore, identifying patients at risk of developing CNR and elucidating its underlying mechanisms remain key priorities. In recent years, our understanding of the human genome has changed considerably, largely due to advances in high-throughput sequencing technologies that have enabled the identification of a broad spectrum of RNA molecules [13, 14]. Importantly, these advances have revealed that only a small fraction of the genome encodes proteins [13–15], whereas approximately 97–99% consists of non-coding sequences [13]. Although non-coding RNAs (ncRNAs) do not encode proteins, they play important roles in the regulation of gene expression and a wide range of cellular processes [13, 15–18]. They are involved in chromatin organization and RNA processing, and act at multiple regulatory levels, including transcriptional and post-transcriptional control [13, 15, 16]. In addition, they participate in epigenetic mechanisms such as DNA methylation and histone modification, thereby contributing to regulatory networks essential for maintaining cellular homeostasis and often implicated in disease development [13, 17, 18]. Non-coding RNAs constitute a heterogeneous group that can be broadly classified into several categories [13, 15, 16]. These molecules can be classified according to their transcript length or functional characteristics [13, 19–21]. Small ncRNAs include microRNAs (miRNAs), small interfering RNAs (siRNAs), and PIWI-interacting RNAs (piRNAs), which are involved mainly in gene silencing and post-transcriptional regulation, although some also exert transcriptional and epigenetic effects [13, 19–21]. In contrast, long non-coding RNAs (lncRNAs) regulate gene expression at multiple levels, including chromatin remodeling, transcriptional control, and post-transcriptional processing [13, 19–21]. Other classes of ncRNAs include small nuclear RNAs (snRNAs), small nucleolar RNAs (snoRNAs), and transfer RNAs (tRNAs). Among all ncRNAs, microRNAs have been the most extensively studied and have been shown to play a key role in the pathophysiology of cardiovascular and other diseases [13, 19–30]. They are approximately 22 nucleotides long and regulate gene expression at the post-transcriptional level by interacting with target mRNAs [31–33]. As powerful regulators of processes such as cell growth, differentiation, development, and apoptosis, they influence essential functions in multiple cell types [34, 35]. Given the growing interest in ncRNAs, increasing attention has been directed toward their potential role in predicting CNR, identifying patients at high risk of adverse clinical outcomes, and improving risk stratification and prognostic assessment. Nevertheless, their clinical application still requires further validation. To our knowledge, the available evidence on the potential utility of ncRNAs in CNR and/or MVO has not yet been comprehensively synthesized. Therefore, we aimed to systematically review the available evidence on the potential clinical utility of ncRNAs in CNR and/or MVO. Methods Eligibility criteria This systematic review was conducted in accordance with the PRISMA 2020 guidelines. We included full-text, English-language observational studies enrolling adult patients with CNR and/or MVO that evaluated the expression of ncRNAs or investigated genetic variants within ncRNA-related pathways. Only studies with an appropriate comparator were considered, including: (1) patients with normal reperfusion after PCI, (2) healthy controls, or (3) within-CNR/MVO comparisons, such as according to the severity of CNR/MVO or infarct size, provided that quantitative differences in ncRNA expression were reported. We excluded book chapters, case reports, commentaries, conference abstracts, editorials, errata, guidelines and statements, letters to the editor, preprints, and reviews, including narrative reviews, systematic reviews, and meta-analyses. We also excluded preclinical studies involving cell lines or animal models, as well as studies performed on human cells stimulated ex vivo. Data reported exclusively in supplementary materials were not extracted. Information sources We searched the following databases: Embase, MEDLINE Ultimate, PubMed, Scopus, and Web of Science. The final search of each database was conducted on February 9, 2026. Search strategy For each database, we used the following search query: “(no-reflow OR “no reflow” OR “microvascular obstruction”) AND (“noncoding RNA*” OR “non-coding RNA*” OR ncRNA* OR microRNA* OR miRNA* OR “micro RNA*” OR lncRNA* OR circRNA* OR “circular RNA” OR siRNA* OR piRNA* OR snoRNA* OR snRNA* OR exRNA* OR scaRNA*)”. Selection process The EndNote automation tool was used to identify duplicate records. Subsequently, AS and DT independently screened all records to identify any remaining duplicates and to exclude records based on article type. AS and DT then independently screened the remaining records based on titles and abstracts to identify potentially eligible studies, followed by full-text assessment for eligibility. In cases of disagreement, final decisions were reached by consensus between the two screeners. If consensus could not be reached, a third reviewer (GP) was consulted. Data collection process AS and DT extracted data from all included studies. Data items We collected data for the following outcomes: differences in ncRNA expression and receiver operating characteristic (ROC) curve statistics: area under the curve (AUC) with 95% CI, sensitivity and specificity. If available, we also extracted other variables for each study: country, setting (single- vs. multi-center), enrollment period, total number of patients and controls, sampling timing, specimen type analyzed, platform used for measurements, control used for normalization. Risk of bias, publication bias and certainty assessment Risk of bias of the included studies was not formally assessed. Publication bias was not evaluated, and no formal assessment of the certainty of evidence was performed. Results The initial search yielded a total of 260 records. After removal of 153 duplicates, 107 records remained and were screened by publication type. Of these, 66 records were excluded, leaving 41 records for title and abstract screening. This resulted in 13 records considered potentially eligible and selected for full-text review. Full texts were successfully retrieved for all of them. After full-text eligibility assessment, 2 studies were excluded: 1 because it was not relevant to the topic [36] and 1 because of its preclinical nature [37]. Ultimately, 11 studies were included in the review [38–48]. The full study selection process is presented in Fig. 1. Study-level characteristics of the included studies are summarized in Table 1. The individual studies are discussed below in chronological order. Flowchart for the selection process. n, number of studies Table 1Study-level characteristics of the included studiesStudyCountrySettingEnrollment periodPopulationComparisonSamplingSpecimen type(s)PlatformControlChen 2025 [48]Chinaprospective cohort and case-control study10.2019–06.202220 STEMI patients with no-reflow80 STEMI patients with normal flow101 age- and sex-matched healthy controlswithin 12 h after admissionserumRT-qPCR, SYBR greenU6Coelho-Lima 2020 [41]UKprospective cohort study01.2017–10.201719 STEMI patients with MVO29 STEMI patients without MVOat the start of PCI procedure and multiple times in the 3-hour period after PCIplasmaRT-qPCR, TaqMann/aDharma 2020 [42]Indonesiaprospective cohort study01.2018–08.2018130 STEMI patients with angiographic MVO87 STEMI without angiographic MVObefore PCIPBMCRT-qPCR, TaqManRNU44Eitel 2012 [38]Germanyprospective cohort study11.2006–02.2008133 STEMI patients with MVO59 STEMI patients without MVObefore PCIserumRT-qPCR,TaqMancel-miR-39Han 2018 [39]Chinaprospective cohort and case-control study04.2014–03.201623 STEMI patients with no-reflow37 STEMI patients with normal flow60 healthy controls24 h and 120 h before and after thrombolytic therapyplasmaRT-qPCRU6Hu 2022 [46]Chinaprospective cohort study01.2018–12.202132 STEMI patients with no-reflow44 STEMI patients with normal flowwithin 1 h of admissionplasmaRT-qPCR, SYBR greenU6Hu 2021 [44]Chinaprospective cohort study01.2016–12.201833 STEMI patients with no-reflow138 STEMI patients with normal flowimmediately after PCIplasmaRT-qPCR, SYBR greencel-miR-67Salama 2020 [43]Egyptprospective cohort and case-control study01.2018–08.201919 STEMI patients with no-reflow21 STEMI patients with normal flow35 patients with chest pain and negative cTnTbefore PCIserumRT-qPCR, SYBR greenn/aSu 2018 [40]Chinaprospective cohort study10.2013–12.201741 STEMI patients with no-reflow214 STEMI patients with normal flowwithin 1 h of admissionplasmaRT-qPCR, SYBR greenU6Yang 2022 [47]Chinaprospective cohort study08.2018–05.202146 STEMI patients with no-reflow152 STEMI patients with normal flowbefore PCIserumRT-qPCR,TaqManβ-actinZhang 2021 [45]Chinaprospective cohort study06.2017–05.201820 STEMI patients with no-reflow32 STEMI patients with normal flowbefore PCIserumRT-qPCRU6β-actin, beta-actin; cTnT, cardiac troponin T; cel-miR-39, Caenorhabditis elegans microRNA-39; cel-miR-67, Caenorhabditis elegans microRNA-67; MVO, microvascular obstruction; n/a, not available; PBMC, peripheral blood mononuclear cells; PCI, percutaneous coronary intervention; RNU44, U44 small nucleolar RNA; RT-qPCR, reverse transcription-quantitative polymerase chain reaction; STEMI, ST-segment elevation myocardial infarction; U6, U6 small nuclear RNA; UK, United Kingdom Study-level characteristics of the included studies 80 STEMI patients with normal flow 101 age- and sex-matched healthy controls RT-qPCR, TaqMan 37 STEMI patients with normal flow 60 healthy controls 21 STEMI patients with normal flow 35 patients with chest pain and negative cTnT RT-qPCR, TaqMan β-actin, beta-actin; cTnT, cardiac troponin T; cel-miR-39, Caenorhabditis elegans microRNA-39; cel-miR-67, Caenorhabditis elegans microRNA-67; MVO, microvascular obstruction; n/a, not available; PBMC, peripheral blood mononuclear cells; PCI, percutaneous coronary intervention; RNU44, U44 small nucleolar RNA; RT-qPCR, reverse transcription-quantitative polymerase chain reaction; STEMI, ST-segment elevation myocardial infarction; U6, U6 small nuclear RNA; UK, United Kingdom Eitel et al. enrolled 216 STEMI patients, 133 of whom developed MVO, diagnosed using cardiac magnetic resonance [38]. Comparison of patients with miR-133a levels above versus below the median showed that higher miR-133a levels were positively associated with MVO occurrence, larger infarct size, a higher incidence of major adverse cardiovascular events (MACE), and increased 6-month mortality. Additionally, patients with a lower LVEF on admission had elevated miR-133a levels. Similarly, Han et al. focused on the association between miR-7a/b and myocardial damage, comparing 23 STEMI patients with the CNR phenomenon and 37 patients who had normal flow [39]. The authors found a significant elevation of miR-7a/b expression in the CNR group. However, the method used to assess CNR was not fully described. In addition, miR-7a/b expression was elevated in all STEMI patients compared with that in a control group of 60 healthy subjects. Further support for the potential role of ncRNAs in CNR prediction came from Su et al., who analyzed miR-30e expression in 41 STEMI patients with the CNR phenomenon and 214 patients with normal reflow post-PCI [40]. CNR was defined as TIMI grade ≤ 2 without significant residual stenosis, mechanical obstruction, or dissection. Significantly lower levels of miR-30e were observed in the CNR group. Reduced miR-30e levels, elevated high-sensitivity C-reactive protein (hs-CRP), and Killip class ≥ 2 were identified as independent risk factors for CNR. ROC analysis indicated that miR-30e was a strong predictor of CNR. Beyond single-candidate biomarker studies, Coelho-Lima et al. identified miRNAs that could serve as prognostic biomarkers following PCI [41]. In the initial screening phase, the authors compared 6 patients with STEMI and MVO versus 6 patients with STEMI without MVO, with MVO diagnosed by cardiac magnetic resonance. A total of 2,083 miRNA transcripts were evaluated, of which 179 circulating miRNAs were selected for further analysis. Ultimately, miR-1 and miR-133b were selected as the main candidates. Both were significantly elevated during the post-reperfusion period. Subsequently, miR-1 and miR-133b were validated in a larger cohort of 48 patients with STEMI, including 19 with MVO. The MVO group exhibited significantly increased levels of both miRNAs following reperfusion. Elevated expression of both miRNAs positively correlated with larger infarct sizes, while higher miR-1 levels were associated with worse left ventricular functional recovery at three months. Likewise, Dharma et al. investigated the relationship between MVO and the expression of miR-224-3p and miR-155-5p [42]. Blood samples were obtained before PCI from 217 STEMI patients, including 130 who were later diagnosed with angiographic MVO. MVO was defined as TIMI grade < 3 or TIMI grade 3 with MBG 0 or 1 after primary PCI. The incidence of MVO was significantly higher in patients with miR-224-3p levels above the median than in those with levels below the median. In contrast, no significant correlation was observed between miR-155-5p levels and the presence of MVO. In another study evaluating the predictive utility of circulating miRNAs, Salama et al. investigated miR-208a as a predictive marker for the CNR phenomenon, evaluating 19 STEMI patients with CNR and 21 with normal flow [43]. CNR was defined as TIMI grade ≤ 1. MiR-208a levels were higher in the CNR group. ROC analysis confirmed miR-208a as a strong predictor of both the CNR phenomenon and MACE. Notably, miR-208a demonstrated superior predictive value for the CNR phenomenon compared with cardiac troponin T (cTnT) and creatine kinase-MB (CK-MB). In addition, miR-208a was elevated in the overall STEMI cohort compared with healthy controls, with ROC analysis highlighting it as a good diagnostic marker for myocardial infarction. Another study was conducted by Hu et al., who examined miR-98-5p as a potential biomarker for the CNR phenomenon [44]. In this study, CNR was defined as TIMI grade ≤ 2. They compared 33 STEMI patients with CNR with 138 patients with normal flow and found that higher miR-98-5p levels were associated with an increased incidence of the CNR phenomenon. When the entire STEMI cohort was compared with 30 healthy controls, patients with STEMI exhibited elevated miR-98-5p expression. Moreover, an in vitro model demonstrated that hypoxia/reoxygenation induced miR-98-5p expression, while in vivo experiments showed that inhibiting miR-98-5p may alleviate microvascular damage. Nevertheless, these findings should be interpreted with caution, since some inconsistencies were noted, which resulted in the publication of a corrigendum [49]. Further, Zhang et al. compared 20 STEMI patients with the CNR phenomenon with 32 patients with normal reflow after PCI [45]. CNR phenomenon was defined as TIMI grade ≤ 2 or TIMI grade 3 with MBG < 2. CNR occurred significantly more often in patients with higher miR-660-5p levels. ROC analysis confirmed miR-660-5p as a good predictive marker for CNR. Moving from individual miRNAs to multimarker models, Hu et al. evaluated the lncRNA TUG1, miR-30e, and NPPB mRNA as potential biomarkers for the CNR phenomenon [46]. They compared 32 STEMI patients with CNR with 44 STEMI patients with normal flow. CNR was defined as TIMI grade ≤ 2 without any significant mechanical obstruction, entrapment, or residual stenosis. The CNR group had significantly elevated expression of TUG1 and NPPB, and decreased expression of miR-30e. The researchers also identified advanced age, low admission LVEF, prolonged pain-to-balloon time, multi-vessel disease, elevated blood glucose, and hs-CRP as risk factors for the CNR phenomenon. A multivariable model combining lncRNA TUG1, miR-30e, and NPPB showed good predictive utility for the incidence of CNR post-PCI (AUC = 0.827). A broader ncRNA panel was assessed by Yang et al., who evaluated the lncRNA MALAT1, miR-30e, miR-126, and miR-155 by comparing 46 STEMI patients with CNR and 152 patients with normal reflow [47]. In this study, the CNR phenomenon was defined as TIMI grade ≤ 2 without significant residual stenosis, mechanical obstruction, or dissection. MiR-30e, miR-126, and miR-155 were significantly lower in the CNR group, whereas MALAT1 expression was higher. ROC analysis showed that miR-30e, miR-126, and MALAT1 could serve as potential biomarkers for the CNR phenomenon. Most recently, Chen et al. evaluated miR-542-3p levels in 100 patients with STEMI [48]. Following PCI, patients were stratified according to TIMI flow grade into a normal reflow group (TIMI 3; n = 80) and a CNR group (TIMI ≤ 2; n = 20). MiR-542-3p expression was significantly lower in the CNR group, suggesting its potential utility as a predictive biomarker of the CNR phenomenon. In addition, when the entire STEMI cohort was compared with 101 age- and sex-matched healthy controls, miR-542-3p was significantly downregulated in the STEMI group and demonstrated good discriminatory performance. Notably, an inconsistency was identified between the main text and the tabulated data regarding NT-proBNP and D-dimer, which may reflect either a typographical error in the main text or in the table. These discrepancies raise concerns about reporting consistency. Discussion The main findings of our study are as follows: (1) ncRNAs are dysregulated in patients with STEMI and CNR/MVO, (2) several ncRNAs may demonstrate good performance in identifying patients at risk of CNR and/or MVO occurrence, (3) miRNAs have been studied the most extensively in this clinical setting, and (4) the available evidence is scarce and limited by the low robustness of the reported findings. The key findings are summarized in Fig. 2. The key findings regarding the role of non-coding RNAs in no-reflow phenomenon. lncRNA, long non-coding RNA; MALAT1, metastasis-associated lung adenocarcinoma transcript 1; miR, microRNA; TUG1, taurine up-regulated 1 The available evidence on ncRNA dysregulation in patients with CNR and/or MVO is summarized in Table 2. Table 2Dysregulated ncRNAs in patients with STEMI and CNR and/or MVO compared with patients without CNR/MVOChangencRNAUpregulated in patients with CNR and/or MVO compared with those without CNR/MVOmiR-1 [41]miR-7a/b [39]miR-98-5p [44]miR-133a [38]miR-133b [41]miR-208a [43]miR-224-3p [42]miR-660-5p [45]lncRNA TUG1 [46]lncRNA MALAT1 [47]Downregulated in patients with CNR and/or MVO compared with those without CNR/MVOmiR-30e [40, 46, 47]miR-126 [47]miR-155 [47]miR-542-3p [48]CNR, coronary no-reflow; lncRNA, long non-coding RNA; MALAT1, metastasis-associated lung adenocarcinoma transcript 1; miR, microRNA; MVO, microvascular obstruction; ncRNA, non-coding RNA; TUG1, taurine up-regulated 1 Dysregulated ncRNAs in patients with STEMI and CNR and/or MVO compared with patients without CNR/MVO miR-1 [41] miR-7a/b [39] miR-98-5p [44] miR-133a [38] miR-133b [41] miR-208a [43] miR-224-3p [42] miR-660-5p [45] lncRNA TUG1 [46] lncRNA MALAT1 [47] miR-30e [40, 46, 47] miR-126 [47] miR-155 [47] miR-542-3p [48] CNR, coronary no-reflow; lncRNA, long non-coding RNA; MALAT1, metastasis-associated lung adenocarcinoma transcript 1; miR, microRNA; MVO, microvascular obstruction; ncRNA, non-coding RNA; TUG1, taurine up-regulated 1 Almost all ncRNAs were reported by a single study, with the exception of miR-30e, which was consistently found to be downregulated in the CNR group in three independent studies [40, 46, 47] and thus warrants further discussion. Wang et al. showed in a rat model that miR-30e expression is reduced after coronary microembolization and that this reduction is accompanied by decreased cardiac function and impaired autophagic activity [50]. These findings suggest that miR-30e may play a role in the pathophysiology of MVO. In another study, miR-30e activated the Notch1/Hes1/Akt pathway, regulated autophagy, and inhibited the caspase cascade, thereby promoting cell survival [51]. Therefore, miR-30e could serve not only as a promising biomarker of the CNR phenomenon, but also as a potential therapeutic target. Our systematic review revealed that several ncRNAs exhibited good predictive value for the CNR phenomenon in patients with STEMI, as summarized in Table 3. The best performance was reported for the lncRNA MALAT1 with an AUC of 0.9587. Again, AUC values for miR-30e were reported in the three abovementioned studies [40, 46, 47], with two independent estimates of 0.914 [40] and 0.848 [47], and one outlying value of 0.752 [46]. From a clinical point of view, a multi-marker approach appears to be the most promising strategy. Hu et al. revealed in a multivariable analysis that the combination of lncRNA TUG1, miR-30e, and NPPB had greater predictive value for CNR than each component alone [46]. Therefore, further studies should focus on validating combinations of ncRNAs and classic biomarkers as panels, which may offer superior predictive performance compared with currently used clinical scores. Table 3Discriminative value of selected non-coding RNAs for distinguishing between no-reflow and normal flow in patients with STEMI, as assessed by ROC analysisncRNAAUC95% CISensitivitySpecificitymiR-30e [46]0.752n/an/an/amiR-30e [40]0.9140.870–0.95782.7%88.6%miR-30e [47]0.8480.81–0.88n/an/amiR-98-5p [44]0.73940.6515–0.827272.73%66.67%miR-126 [47]0.82190.77–0.85n/an/amiR-155 [47]0.54450.49–0.60n/an/amiR-208a [43]0.8750.732–0.95873.68%95.24%miR-660-5p [45]0.7680.636–0.89070%75%lncRNA TUG1 [46]0.785n/an/an/alncRNA MALAT1 [47]0.95870.94–0.98n/an/aAUC, area under the ROC curve; CI, confidence interval; lncRNA, long non-coding RNA; MALAT1, metastasis-associated lung adenocarcinoma transcript 1; miR, microRNA; n/a, not available; ncRNA, non-coding RNA; ROC, receiver operating characteristic; TUG1, taurine up-regulated 1 Discriminative value of selected non-coding RNAs for distinguishing between no-reflow and normal flow in patients with STEMI, as assessed by ROC analysis AUC, area under the ROC curve; CI, confidence interval; lncRNA, long non-coding RNA; MALAT1, metastasis-associated lung adenocarcinoma transcript 1; miR, microRNA; n/a, not available; ncRNA, non-coding RNA; ROC, receiver operating characteristic; TUG1, taurine up-regulated 1 The role of ncRNAs in STEMI may extend beyond the prediction of CNR, as they could also be used as biomarkers for long-term risk stratification. As demonstrated by Eitel et al. [38], miR-133a was associated not only with the incidence of MVO, but also with a higher incidence of MACE, increased 6-month mortality, and larger infarct size. This indicates that ncRNAs could serve as potential biomarkers for more precise risk stratification and for identifying patients after PCI who may require more intensive care or closer follow-up. All included studies focused exclusively on STEMI patients. Even though the CNR phenomenon occurs predominantly in STEMI patients undergoing PCI, it may also be observed in non-ST-segment elevation myocardial infarction (NSTEMI) patients and after PCI for chronic coronary syndromes (CCS). The pathophysiology of CNR in elective PCI may differ from that in STEMI; therefore, the utility of ncRNAs in predicting CNR phenomenon in these settings warrants further investigation. Further studies should therefore also include other clinical phenotypes, particularly NSTEMI and CCS populations. The available evidence that we systematically reviewed should be interpreted in the context of its limitations. First, the limited number of studies and relatively small cohorts may limit the robustness of the findings. At the same time, the inclusion of studies from different countries may enhance the generalizability of the findings across ethnically diverse populations. Second, the lack of standardized protocols for ncRNA isolation and quantification hampers direct comparisons between studies. Third, differences in blood sampling timing, particularly given the dynamic kinetics of ncRNA release, might have influenced the reported results. Fourth, heterogeneous definitions of CNR and MVO were used in the included studies, which further limited comparability. Fifth, most ncRNAs were reported in single studies, limiting reproducibility. Sixth, data presentation also varied between studies; some did not directly report differences in ncRNA expression according to CNR status, but instead reported the prevalence of CNR across ncRNA expression groups. Accordingly, some assumptions were required when summarizing the evidence in Table 2. Conclusions Circulating ncRNAs are promising biomarkers for CNR after PCI in STEMI patients. A panel of ncRNAs, preferably combined with other factors, might become a prognostic tool enabling early identification of patients at high risk of developing the CNR phenomenon and subsequent MACE. Nevertheless, several limitations persist, including the lack of methodological standardization, differences in CNR and MVO definitions, variability in blood collection timing, and lack of well-defined laboratory protocols. These limitations highlight the need for further studies with standardized methodology to assess the clinical utility of ncRNAs. Acknowledgements Figure (1) Created in BioRender. Procyk, G. (2026) https://BioRender.com/gs145v3 Figure (2) Created in BioRender. Procyk, G. (2026) https://BioRender.com/n0v55tz. Author contributions Author Contributions: Adam Sukiennik: Conceptualization, Methodology, Software, Formal analysis, Investigation, Resources, Data Curation, Writing – Original Draft Preparation. Dominika Tomkiel: Methodology, Software, Formal analysis, Investigation, Resources, Data Curation, Writing – Original Draft Preparation. Grzegorz Procyk: Conceptualization, Methodology, Software, Validation, Writing – Review and Editing, Visualization, Supervision, Project administration, Funding acquisition. All authors participated in the research and preparation of the manuscript. All authors edited and approved the final version of the manuscript. Funding This study received no funding. Data availability All extracted data are available from the corresponding author upon request. Declarations Ethics approval and consent to participate The manuscript does not contain clinical studies or patient data. Competing interests The authors declare no competing interests. Registration and protocol The protocol for this review was not prepared and the review was not registered. Declaration of generative AI and AI-assisted technologies in the manuscript preparation process We used an AI-based language model (ChatGPT, OpenAI) to assist with minor language editing of the manuscript text; the authors reviewed and edited the content as needed and take full responsibility for the content of the published article. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Availability Statement All extracted data are available from the corresponding author upon request.